. 2022 Apr 25;11:e70810. doi: 10.7554/eLife.70810

Table 3. Hub cell fate conversion after EGFR pathway activation.

Gal4 driver	UAS lines (BDSC #)	Days at 29 °C	% Testes with GFP-marked cells outside the hub
E132-Gal4, Gal80^ts	UAS-G-TRACE (28280)	8	0% (n = 0/39)
	UAS-G-TRACE (28280); UAS-Egfr Type II (9533)		61% (n = 19/31)****
	UAS-G-TRACE (28280); UAS-Pointed.P1 (869)		38% (n = 19/50)****
	UAS-G-TRACE (28280); UAS-Pointed.P2 (399)		22% (n = 4/18)**
	UAS-G-TRACE (28280); UAS-Sprouty-RNAi (36709)		36% (n = 32/89)****
	UAS-G-TRACE (28280); UAS- Pten-RNAi (33643)		18% (n = 6/34)**
E132-Gal4, Gal80^ts	UAS-G-TRACE (28281)	8	0% (n = 0/84)
E132-Gal4, Gal80^ts	UAS-Egfr Type I (9534); UAS-G-TRACE (28281)	8	2% (n = 1/47)^ns

Percentages in bold are significant compared to the negative control (corresponding UAS-G-TRACE alone).

Fisher’s Exact Test: **p < 0.01, ****p < 0.0001, ns = not significant.